TeleHealth Med Review

TeleHealth Med: the rare provider that admits its testimonials are paid

Most GLP-1 telehealth sites bury you in glowing before-and-after stories and hope you don't ask who those people are. TeleHealth Med does something almost no competitor does: right on its homepage it states that its testimonials are compensated and that individual results were never independently verified. That one line of honesty tells you more about how this Georgia company operates than any five-star quote could. If you value a provider that levels with you over one that polishes every claim, TeleHealth Med earns a serious look — with a few real gaps you should know about first.

Pricing starts at $147 a month, which lands a touch under the $170 category median. It's a budget-friendly entry point for compounded GLP-1 care, and the program bundles the medication, clinician access, and shipping into that figure rather than nickel-and-diming you with add-ons.

How the pricing actually works

The headline number you'll see is "as low as $147/month" for the TeleHealth Med GLP-1 program. Treat that as the floor, not the whole story. The company doesn't publish its higher dose tiers, and it doesn't list separate pricing for compounded tirzepatide at all — so the semaglutide starting rate is the only concrete price you can plan around today. There's no teaser first-month rate dangled to lure you in, which is refreshing, but it also means you should call or check the portal to confirm what your actual dose will cost before you commit.

What's included is straightforward: the medication, virtual appointments, continuous live support, and free rapid delivery all fall under the monthly price. Crucially, TeleHealth Med accepts HSA and FSA cards — still uncommon in compounded GLP-1 land — so you may be able to pay with pre-tax dollars. No insurance is required, and all major credit cards work.

Injectable or sublingual — both are on the table

TeleHealth Med dispenses compounded semaglutide and tirzepatide in two forms: the standard weekly injection and a sublingual (under-the-tongue) version for people who'd rather skip needles entirely. Its FAQ walks through how the two differ, so this isn't a throwaway marketing line — both are genuinely offered. The medications are filled by 503A compounding pharmacies that, per the company, are FDA-regulated and licensed by their state boards.

One honest caveat: because these are compounded drugs, they carry the standard disclaimer that TeleHealth Med itself prints repeatedly on its site — the FDA has not approved or evaluated compounded medications for safety, quality, or effectiveness. That's true of every compounding-based competitor, but it's worth seeing it stated plainly rather than hidden.

What sets TeleHealth Med apart

Beyond the paid-testimonial disclosure, the differentiator here is accountability you can actually trace. The footer names a real corporate entity — TeleHealth Med, Inc. — based in Evans, Georgia, which is more than a lot of anonymous storefronts will give you. It carries an active LegitScript verification link, prints the FDA compounded-medication disclaimer, states its 503A pharmacy designation, and publishes a phone number with business-hours coverage and a support email. Its clinicians are described as licensed, board-certified, and US-based. Stacked together, those are the signals of a company comfortable being identified.

• Disclosed corporate entity (TeleHealth Med, Inc.) and a real Georgia base
• Both injectable and sublingual semaglutide and tirzepatide
• HSA/FSA accepted — pay with pre-tax dollars
• Published phone line and email, not just a contact form
• Candid, on-site admission that testimonials are compensated and unverified

Where it falls short

Honesty about testimonials doesn't erase some transparency gaps. TeleHealth Med doesn't name the specific 503A pharmacy that fills your prescription, doesn't show its LegitScript ID number in plain text (only the verification link), and doesn't publish a full list of states it serves or name a medical director. Its dose tiers above the starting price aren't disclosed, and tirzepatide pricing is missing from the homepage entirely. The refund policy is also on the strict side: no refunds for partially used subscription periods or bundled packages, and promotional discounts can be clawed back proportionally if you cancel.

Two promotional figures on the site — claims of 100,000-plus treatments filled and a high patient-achievement rate — are not independently verified, so weigh them the same way the company itself tells you to weigh its testimonials.

Who should choose it — and who should skip it

Choose TeleHealth Med if you want an affordable compounded GLP-1 program from a named, LegitScript-listed company, you'd like the option of a sublingual formulation, and you want to pay with an HSA or FSA. The transparent corporate footprint and the unusual candor make it a sensible pick for cautious first-timers on a budget.

Skip it if you need to know exactly which pharmacy compounds your medication, want a named medical director on record, or need confirmed pricing for tirzepatide or higher doses before you sign up. Anyone who expects a flexible, money-back-style refund policy should also read the cancellation terms closely first.

The bottom line

TeleHealth Med won't win on disclosure depth — the unnamed pharmacy, missing LegitScript ID, and undisclosed states-served list keep our confidence at a measured level rather than the top tier. But few competitors at this price are this upfront about their own marketing, and the combination of a real corporate entity, dual injectable/sublingual options, HSA/FSA acceptance, and a starting rate just under the category median makes it a credible, budget-conscious choice. Just confirm your specific dose, drug, and refund terms in writing before your first charge. For how we weigh these factors, see our scoring methodology.

Worth pricing against Yucca Health ($146/month) and bmiMD ($99/month) before you commit — both sit close to TeleHealth Med on cost and formulation.